Pfizer Inc.

PFE · NYSE · USD

Can Pfizer's newer drugs, monthly obesity injection and cost savings replace the revenue lost as Eliquis, Vyndamax and other large products lose exclusivity by 2028?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Padcev bladder cancer label

    The bull case on oncology is that Padcev now treats bladder cancer from early muscle-invasive through metastatic disease, so one regimen reaches far more patients.

  • Monthly obesity injection

    In obesity, the argument is that a monthly injection is easier to stay on and Pfizer's primary care reach makes it a credible late entrant in a young market.

  • Vyndamax patent settlement

    The Vyndamax settlement pushes generic competition out by years, giving management a base from which it says revenue can grow again after 2028.

  • Cost savings fund the pipeline

    Cost programs have been expanded and extended, and the bull case is that these savings pay for the pipeline and obesity studies without margin damage.

Bear case

  • Falling COVID product sales

    COVID products keep shrinking and management has cut its own forecast for them again, so the company replaces those sales from a lower starting point than planned.

  • Late-stage trial failures

    Late-stage failures have already forced large write-downs on assets bought to replace lost revenue, and each miss pushes the growth restart further out.

  • Debt limits buybacks

    With debt staying high until the exclusivity losses pass, cash goes to the dividend and small deals, and buybacks that would lift per-share results stay on hold.

Bull and bear points

Growth & Execution

In short: New drugs and a monthly obesity injection are growing while COVID revenue keeps falling faster than planned.

Bull · 2

  • Padcev approval covers all bladder cancer patients

    The label now spans early muscle-invasive and metastatic disease regardless of cisplatin eligibility, which widens the eligible population and lets one sales force sell a single regimen across the treatment pathway.

    Q2 FY2026 call

  • Ten Phase III studies planned for obesity drug

    A once-monthly injection would be easier to stay on than weekly options, and management plans ten Phase III studies this year, including one that switches patients off weekly medicines.

    Q2 FY2026 call
Bear · 2

  • COVID revenue guidance cut again for 2026

    A quarter ago management expected about $5 billion of COVID revenue this year; it now guides to about $4 billion, so the product line keeps absorbing forecast cuts instead of stabilizing.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Lung cancer ADC missed its survival goal

    The integrin beta-6 antibody-drug conjugate did not meet overall survival in second-line lung cancer, so a late-stage asset counted on to replace lost revenue now rests on other trials.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Cash flow covers the dividend and cost savings are expanding, but debt stays high and buybacks are on hold.

Bull · 2

  • Cost savings target raised to $9.7 billion

    Savings that were due to finish in 2026 now run through 2029, helping operating margin reach 31.3% in the latest quarter even as research spending rose.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Free cash flow covers the dividend

    Free cash flow of $11.0 billion over the past year funds the payout, and management has committed to maintaining the dividend through the patent-loss period.

    Q2 FY2026 call
Bear · 2

  • Leverage stays high through the patent cliff

    Net debt of $54.9 billion and leverage near 2.7 times leave little room for buybacks, because management expects debt to stay at current levels or rise until the exclusivity losses pass.

    Q2 FY2026 call

  • Pipeline write-downs keep hitting earnings

    Two quarters in a row carried large non-cash impairments on acquired and in-development assets, which shows how much of the deal-led pipeline has yet to prove itself.

    Q2 FY2026 call

Market Position

In short: Settlements extend heart-drug exclusivity, but patent expiries and U.S. pricing policy still weigh on revenue.

Bull · 1

  • Vyndamax settlement adds years of exclusivity

    Generic competition on the heart drug was expected in 2028; the settlements push it out, and management now points to high single-digit revenue growth starting in 2029.

    Tone shiftQ4 FY2025 → Q1 FY2026
Bear · 2

  • Exclusivity losses accelerate from 2026 to 2030

    Several large products lose patent or regulatory protection in that window, and with Eliquis the biggest single product, the revenue hole is wide enough to shrink the whole company for years.

    10-K, filed 2026-02-26

  • U.S. pricing agreement lowers prices

    The agreement with the U.S. government lowers prices on Pfizer medicines and management expects it to dilute 2026 results, adding a policy drag on top of patent losses.

    Q3 FY2025 call